Association of a Combined Plasma EBV DNA and Tumor Volume Index with Progression-Free Survival in Stage II–III Nasopharyngeal Carcinoma: An Exploratory Single-Center Analysis

Background and Objectives: Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated malignancy whose outcome varies beyond TNM staging. Pretreatment plasma EBV DNA load and gross tumor volume (GTV) are each associated with outcome. We examined their combined prognostic value using the EBV–Volume Index (EVI), defined as EVI = Ln[(EBV DNA + 1) × GTVt]. Materials and Methods: This retrospective single-center study included 70 consecutive patients with stage II–III NPC treated with definitive intensity-modulated radiotherapy, with or without chemotherapy, between June 2014 and January 2025. Progression-free survival (PFS) was the primary endpoint, and overall survival (OS) was the secondary endpoint. EVI was analyzed as a continuous variable using Cox regression, unadjusted and adjusted for TNM stage. A dichotomized EVI threshold, derived from a censoring-aware time-dependent ROC analysis at 60 months, was used for exploratory analyses and visualization. Results: Median follow-up was 70 months, with 28 PFS events and 19 deaths. Each one-unit increase in EVI was associated with shorter PFS (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.06–1.37; p = 0.005), corresponding to an HR of 1.93 (95% CI, 1.22–3.05) per standard deviation. This association persisted after adjustment for TNM stage (HR 1.17, 95% CI 1.02–1.34; p = 0.021). For OS, the association was similar in direction and size after the same adjustment for TNM stage but did not reach statistical significance (HR, 1.17; 95% CI, 1.00–1.37; p = 0.055). Patients with EVI ≥ 12.41 had shorter median PFS (43 months vs. not reached; log-rank p = 0.003); however, this threshold was derived from the same cohort and is not proposed for clinical use. Conclusions: In this cohort, a combined pretreatment EBV DNA and tumor volume index was associated with PFS after adjustment for TNM stage. In models containing TNM stage, EVI discriminated better than plasma EBV DNA entered alone (optimism-corrected C-index 0.739 vs. 0.706; difference +0.033, 95% CI +0.004 to +0.071), indicating that the volumetric component contributes information that viral load alone does not. These findings are hypothesis-generating and require external validation before clinical application.

Authors

Institutions

Publication Details

Journal
Medicina
Published
2026-11-19
DOI
https://doi.org/10.3390/medicina62112280
Primary Topic
Head and Neck Cancer Studies
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Association of a Combined Plasma EBV DNA and Tumor Volume Index with Progression-Free Survival in Stage II–III Nasopharyngeal Carcinoma: An Exploratory Single-Center Analysis

Oğuz Çetinayak, Faruk Recep Özalp, mehmet varol, Mehmet Çağrı Duymaz et al.
Medicina
Head and Neck Cancer Studies
article

Association of a Combined Plasma EBV DNA and Tumor Volume Index with Progression-Free Survival in Stage II–III Nasopharyngeal Carcinoma: An Exploratory Single-Center Analysis

Oğuz Çetinayak, Faruk Recep Özalp, mehmet varol, Mehmet Çağrı Duymaz, Ece Özkaya Duymaz, Halit Can Koç
article en

Abstract

Background and Objectives: Nasopharyngeal carcinoma (NPC) is an Epstein–Barr virus (EBV)-associated malignancy whose outcome varies beyond TNM staging. Pretreatment plasma EBV DNA load and gross tumor volume (GTV) are each associated with outcome. We examined their combined prognostic value using the EBV–Volume Index (EVI), defined as EVI = Ln[(EBV DNA + 1) × GTVt]. Materials and Methods: This retrospective single-center study included 70 consecutive patients with stage II–III NPC treated with definitive intensity-modulated radiotherapy, with or without chemotherapy, between June 2014 and January 2025. Progression-free survival (PFS) was the primary endpoint, and overall survival (OS) was the secondary endpoint. EVI was analyzed as a continuous variable using Cox regression, unadjusted and adjusted for TNM stage. A dichotomized EVI threshold, derived from a censoring-aware time-dependent ROC analysis at 60 months, was used for exploratory analyses and visualization. Results: Median follow-up was 70 months, with 28 PFS events and 19 deaths. Each one-unit increase in EVI was associated with shorter PFS (hazard ratio [HR], 1.21; 95% confidence interval [CI], 1.06–1.37; p = 0.005), corresponding to an HR of 1.93 (95% CI, 1.22–3.05) per standard deviation. This association persisted after adjustment for TNM stage (HR 1.17, 95% CI 1.02–1.34; p = 0.021). For OS, the association was similar in direction and size after the same adjustment for TNM stage but did not reach statistical significance (HR, 1.17; 95% CI, 1.00–1.37; p = 0.055). Patients with EVI ≥ 12.41 had shorter median PFS (43 months vs. not reached; log-rank p = 0.003); however, this threshold was derived from the same cohort and is not proposed for clinical use. Conclusions: In this cohort, a combined pretreatment EBV DNA and tumor volume index was associated with PFS after adjustment for TNM stage. In models containing TNM stage, EVI discriminated better than plasma EBV DNA entered alone (optimism-corrected C-index 0.739 vs. 0.706; difference +0.033, 95% CI +0.004 to +0.071), indicating that the volumetric component contributes information that viral load alone does not. These findings are hypothesis-generating and require external validation before clinical application.

MedicinaVol. 62(11)
Dokuz Eylül University (TR)
Head and Neck Cancer Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon